Latest News for: cartesianism

Edit

Statement of Changes in Beneficial Ownership (Form 4) (Cartesian Therapeutics Inc)

Public Technologies 21 Mar 2025
) FORM 4. Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b) ... See Instruction 10. UNITED STATES SECURITIES AND EXCHANGE COMMISSION ... 0.5 ... Cartesian Therapeutics, Inc ... Cartesian Therapeutics Inc.
Edit

Cartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Nasdaq Globe Newswire 13 Mar 2025
Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25; Deep and durable responses maintained over 12 months in Descartes-08-treated participants in Phase 2b trial ... .
Edit

Cartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update (Form 8-K) (Cartesian Therapeutics Inc)

Public Technologies 13 Mar 2025
) Cartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update ... Frederick, MD, March 13, 2025 (GLOBE NEWSWIRE) - Cartesian Therapeutics, Inc ... About Cartesian Therapeutics ... Cartesian Therapeutics Inc.
Edit

March 2025 Corporate Presentation (Cartesian Therapeutics Inc)

Public Technologies 13 Mar 2025
). Pioneering mRNA Cell Therapy for Autoimmunity. March 2025. MULTIPLE ANTICIPATED NEAR-TERM CATALYSTS. Clinical-stage company pioneering mRNA cell therapies designed ... 3 ... Cartesian's mRNA approach is designed to expand the ... 4 ... 5 ... 6 ... Cartesian Therapeutics Inc.
Edit

Annual Report for Fiscal Year Ending December 31, 2024 (Form 10-K) (Cartesian Therapeutics Inc)

Public Technologies 13 Mar 2025
Pursuant to the Merger Agreement, First Merger Sub merged with and into Old Cartesian, pursuant to which Old Cartesian was the surviving corporation and became a wholly owned subsidiary of Selecta ... Cartesian Therapeutics Inc.
Edit

Cartesian Therapeutics Announces New Employment Inducement Grant

MENA FN 06 Mar 2025
(MENAFN - GlobeNewsWire - Nasdaq) FREDERICK, Md., March 06, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ. RNAC) (the–Company–), a clinical-stage biotechnology company pioneering ... .
Edit

Regulation FD Presentation (Form 8-K) (Cartesian Therapeutics Inc)

Public Technologies 03 Mar 2025
). The text version of this document is not available ... Cartesian Therapeutics Inc.
Edit

Material Event (Form 8-K) (Cartesian Growth Corporation II)

Public Technologies 03 Mar 2025
On February 28, 2025, Cartesian Growth Corporation II (the ... Cartesian Growth Corporation II published this content on March 03, 2025, and is solely responsible for the information contained therein.
Edit

TD Cowen 45th Annual Healthcare Conference Presentation (Cartesian Therapeutics Inc)

Public Technologies 03 Mar 2025
). Pioneering mRNA Cell Therapy for Autoimmunity. March 2025. MULTIPLE ANTICIPATED NEAR-TERM CATALYSTS. Clinical-stage company pioneering mRNA cell therapies designed ... 3 ... Cartesian's mRNA approach is designed to expand the ... 4 ... 5 ... 6 ... Cartesian Therapeutics Inc.
  • 1
×